2026-04-14T02:26:51Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1330772025-12-05T13:11:14Zcom_2072_1057col_2072_478798col_2072_478917
Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination.
Hanquet, Germaine
Krizova, Pavla
Valentiner-Branth, Palle
Ladhani, Shamez N.
Nuorti, J. Pekka
Lepoutre, Agnes
Mereckiene, Jolita
Knol, Mirjam
Winje, Brita A.
Ciruela, Pilar
Ordobas, Maria
Guevara, Marcela
McDonald, Eisin
Morfeldt, Eva
Kozakova, Jana
Slotved, Hans-Christian
Fry, Norman K.
Rinta-Kokko, Hanna
Varon, Emmanuelle
Corcoran, Mary
Van der Ende, Arie
Vestrheim, Didrik F.
Muñoz-Almagro, Carmen
Latasa, Pello
Castilla, Jesús
Smith, Andrew
Henriques-Normark, Birgitta
Whittaker, Robert
Pastore Celentano, Lucia
Savulescu, Camelia
SpIDnet/I-MOVE+ Pneumo Group
Malalties bacterianes
Epidemiologia
Vacuna antipneumocòccica
Adults
Infància
Europa
Bacterial diseases
Epidemiology
Pneumococcal vaccine
Adulthood
Childhood
Europe
Background: pneumococcal conjugate vaccines (PCVs) have the potential to prevent pneumococcal disease through direct and indirect protection. This multicentre European study estimated the indirect effects of 5-year childhood PCV10 and/or PCV13 programmes on invasive pneumococcal disease (IPD) in older adults across 13 sites in 10 European countries, to support decision-making on pneumococcal vaccination policies. Methods: for each site we calculated IPD incidence rate ratios (IRR) in people aged ≥65 years by serotype for each PCV10/13 year (2011-2015) compared with 2009 (pre-PCV10/13). We calculated pooled IRR and 95% CI using random-effects meta-analysis and PCV10/13 effect as (1 - IRR)*100. Results: after five PCV10/13 years, the incidence of IPD caused by all types, PCV7 and additional PCV13 serotypes declined 9% (95% CI -4% to 19%), 77% (95% CI 67% to 84%) and 38% (95% CI 19% to 53%), respectively, while the incidence of non-PCV13 serotypes increased 63% (95% CI 39% to 91%). The incidence of serotypes included in PCV13 and not in PCV10 decreased 37% (95% CI 22% to 50%) in six PCV13 sites and increased by 50% (95% CI -8% to 146%) in the four sites using PCV10 (alone or with PCV13). In 2015, PCV13 serotypes represented 20-29% and 32-53% of IPD cases in PCV13 and PCV10 sites, respectively. Conclusion: overall IPD incidence in older adults decreased moderately after five childhood PCV10/13 years in 13 European sites. Large declines in PCV10/13 serotype IPD, due to the indirect effect of childhood vaccination, were countered by increases in non-PCV13 IPD, but these declines varied according to the childhood vaccine used. Decision-making on pneumococcal vaccination for older adults must consider the indirect effects of childhood PCV programmes. Sustained monitoring of IPD epidemiology is imperative.
2019-05-13T11:57:12Z
2019-05-13T11:57:12Z
2019-05
2019-05-13T11:57:12Z
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
0040-6376
https://hdl.handle.net/2445/133077
685543
30355641
eng
Reproducció del document publicat a: https://doi.org/10.1136/thoraxjnl-2018-211767
Thorax, 2019, vol. 74, num. 5, p. 211767
https://doi.org/10.1136/thoraxjnl-2018-211767
info:eu-repo/grantAgreement/EC/H2020/634446/EU//I-MOVE-plus
(c) BMJ Publishing Group, 2019
info:eu-repo/semantics/openAccess
10 p.
application/pdf
BMJ Publishing Group
Articles publicats en revistes (Ciències Clíniques)